Northwire Canada EditionFriday, July 10, 2026

Sign in Subscribe

FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%

Financings Admin

Doseology extends financing, president Corkum resigns

By The Northwire Desk — AI Analysis May 15, 2026 · 22:24 MOOD · 0.4 Doseology Sciences Inc

MOOD · Price

Executive Summary

Doseology Sciences Inc. has received a 45-day extension from the Canadian Securities Exchange (CSE) to close its non-brokered private placement.
The company announced the resignation of Tim Corkum as President and Chief Operating Officer, effective April 28, 2026.

Key Details

Private Placement Extension:
- Extension Duration: 45 days from the CSE
- Offering Size: Up to 3,225,806 units
- Price per Unit: $0.62
- Target Gross Proceeds: Up to $2 million
Management Change:
- Outgoing Officer: Tim Corkum (President and Chief Operating Officer)
- Effective Date: April 28, 2026

Read the original news release →

More from Doseology Sciences Inc

Jun 29, 2026 · 19:21

Doseology Announces Extension to Closing of Private Placement

Financings Mar 11, 2026 · 16:48

Doseology shares begin trading on OTCQB Venture Market

Financings Mar 11, 2026 · 07:00

Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category

Financings Mar 04, 2026 · 13:13

Doseology Sciences rolls out Feed That Brain product

Other Mar 04, 2026 · 07:00

Doseology Launches Feed That Brain(TM) Oral Stimulant Pouches in the U.S. Through Direct-to-Consumer Pilot

Other Feb 27, 2026 · 16:05

SEDAR Interim Financial Statements